Akumin Inc. (AKU)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Akumin Inc. (AKU) trades at $0.29 with AI Score 53/100 (Grade B). Akumin Inc. is a leading provider of outpatient diagnostic imaging services in the United States, operating through a network of approximately 200 owned and/or operated imaging locations. Market cap: $26.27M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for AKU: AKU does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AKU against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
AKU: 3/7 perspectives are bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Akumin Inc. (AKU) Healthcare & Pipeline Overview
Akumin Inc. delivers outpatient diagnostic imaging services in the U.S., offering radiology and oncology solutions to hospitals and health systems. With a network of 200 locations, the company provides MRI, CT, and other imaging modalities. Despite negative profitability, Akumin plays a crucial role in healthcare diagnostics.
What Is the Investment Thesis for AKU?
Akumin Inc. presents a complex investment case. While the company plays a vital role in providing outpatient diagnostic imaging services, its financial performance raises concerns. With a market capitalization of $26.27M and a negative P/E ratio of -0.17, the company's profitability is a significant challenge, further highlighted by a negative profit margin of -20.2%. The company's gross margin stands at 18.8%. Potential growth catalysts include expanding its network of imaging locations and increasing service offerings. However, the company must address its profitability issues to ensure long-term sustainability. Investors should closely monitor Akumin's ability to improve its financial performance and capitalize on growth opportunities in the diagnostic imaging market.
Based on FMP financials and quantitative analysis
AKU Key Highlights
- Akumin operates approximately 200 owned and/or operated imaging locations across the United States.
- The company provides services to approximately 1,000 hospitals and health systems in 46 states.
- Akumin's market capitalization is $0.03 billion, reflecting its current market valuation.
- The company's P/E ratio is -0.17, indicating negative earnings.
- Akumin's profit margin is -20.2%, highlighting profitability challenges.
Who Are AKU's Competitors?
AKU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNTG Centogene N.V. | $0.33 | +100.00% | $9.42M | 50 |
| LMDX LumiraDx Limited | $0.02 | +0.00% | $5.10M | 46 |
| PRE Prenetics Global Limited | $17.25 | +1.88% | $293.23M | 69 |
| EPGNY Epigenomics AG | $2.39 | +0.00% | 68 | |
| STRRP Star Equity Holdings, Inc. | $9.89 | -0.10% | $40.58M | 68 |
| TWST Twist Bioscience Corporation | $100.97 | +1.74% | $6.29B | 65 |
| CLIFF Cordlife Group Limited | $0.15 | +0.00% | $38.57M | 53 |
| CEMI Chembio Diagnostics, Inc. | $0.46 | +0.22% | $16.71M | 53 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AKU's Key Strengths?
- Extensive network of imaging centers.
- Established relationships with hospitals and health systems.
- Comprehensive range of diagnostic imaging services.
- Presence in multiple states across the United States.
What Are AKU's Weaknesses?
- Negative profit margin.
- High debt levels.
- Dependence on reimbursement rates.
- Competition from larger imaging providers.
What Could Drive AKU Stock Higher?
- Expansion of imaging center network through acquisitions and new site development.
- Implementation of new technologies to improve diagnostic accuracy and efficiency.
- Potential partnerships with healthcare providers to expand referral network.
- Focus on oncology services to capitalize on growing demand for cancer diagnostics and treatment.
What Are the Key Risks for AKU?
- Financial-distress signal — its Altman Z-Score of -1.00 sits in the distress zone (elevated bankruptcy risk).
- Changes in reimbursement policies affecting revenue and profitability.
- Increased competition from other imaging providers.
- Economic downturn affecting healthcare spending.
- Technological obsolescence requiring significant capital investment.
- Integration risks associated with acquisitions.
What Are the Growth Opportunities for AKU?
- Expansion of Service Offerings: Akumin can expand its service offerings to include more specialized diagnostic procedures and interventional radiology services. This would allow the company to attract a broader range of patients and increase revenue per location. The market for specialized diagnostic services is growing, driven by advancements in medical technology and increasing demand for personalized medicine. Timeline: 1-2 years. Market Size: $10 billion annually.
- Strategic Acquisitions: Akumin can pursue strategic acquisitions of smaller imaging centers and radiology practices to expand its geographic footprint and market share. This would allow the company to enter new markets and consolidate its position in existing markets. The market for imaging center acquisitions is active, with numerous opportunities available. Timeline: Ongoing. Market Size: $5 billion annually.
- Technological Upgrades: Investing in advanced imaging technologies, such as AI-powered diagnostic tools and high-resolution imaging systems, can improve the accuracy and efficiency of Akumin's services. This would allow the company to attract more patients and improve patient outcomes. The market for advanced imaging technologies is growing rapidly. Timeline: 1-3 years. Market Size: $3 billion annually.
- Partnerships with Healthcare Providers: Akumin can form strategic partnerships with hospitals, physician groups, and other healthcare providers to expand its referral network and increase patient volume. This would allow the company to access a larger pool of patients and integrate its services into the broader healthcare ecosystem. Timeline: Ongoing. Market Size: $2 billion annually.
- Focus on Oncology Services: Akumin can focus on expanding its oncology services, such as PET/CT imaging and radiation therapy, to capitalize on the growing demand for cancer diagnostics and treatment. This would allow the company to tap into a high-growth market segment and improve its profitability. The market for oncology services is growing rapidly. Timeline: 2-3 years. Market Size: $7 billion annually.
What Opportunities Does AKU Have?
- Expansion into new geographic markets.
- Increased demand for outpatient imaging services.
- Technological advancements in diagnostic imaging.
- Partnerships with healthcare providers and payers.
What Threats Does AKU Face?
- Changes in reimbursement policies.
- Increased competition from other imaging providers.
- Economic downturn affecting healthcare spending.
- Technological obsolescence.
What Are AKU's Competitive Advantages?
- Extensive network of approximately 200 imaging locations.
- Relationships with approximately 1,000 hospitals and health systems.
- Comprehensive suite of diagnostic imaging services.
- Established presence in 46 states across the United States.
What Does AKU Do?
Akumin Inc., founded in 2015 and headquartered in Plantation, Florida, is a prominent provider of outpatient diagnostic imaging services in the United States. The company operates through two primary segments: Radiology and Oncology. Akumin offers a comprehensive suite of medical imaging services, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, digital radiography, fluoroscopy, and various other diagnostic and interventional radiology procedures. These services are delivered through a network of approximately 200 owned and/or operated imaging locations. Akumin's services cater to a broad spectrum of healthcare needs, supporting the diagnostic and treatment pathways for numerous medical conditions. The company partners with approximately 1,000 hospitals and health systems across 46 states, providing them with outpatient radiology and oncology services and solutions. This extensive network allows Akumin to reach a significant patient population and contribute to the efficiency and effectiveness of healthcare delivery. The company's focus on outpatient services aims to provide convenient and cost-effective access to essential diagnostic imaging, reducing the burden on hospital resources and improving patient outcomes. Akumin's commitment to innovation and quality in diagnostic imaging has positioned it as a key player in the evolving healthcare landscape.
What Products and Services Does AKU Offer?
- Provides outpatient diagnostic imaging services.
- Offers magnetic resonance imaging (MRI) services.
- Performs computed tomography (CT) scans.
- Conducts positron emission tomography (PET) scans.
- Offers nuclear medicine services.
- Provides mammography and ultrasound services.
- Delivers digital radiography and fluoroscopy procedures.
- Offers interventional radiology procedures.
How Does AKU Make Money?
- Generates revenue by providing diagnostic imaging services to patients.
- Contracts with hospitals and health systems to provide outpatient radiology and oncology solutions.
- Operates a network of owned and/or operated imaging locations.
- Focuses on outpatient services to provide convenient and cost-effective access to diagnostic imaging.
What Industry Does AKU Operate In?
The medical diagnostics and research industry is experiencing growth driven by technological advancements, an aging population, and increasing prevalence of chronic diseases. Companies like Akumin play a crucial role in providing essential diagnostic imaging services. The industry is competitive, with players like ABDXF (Abdos Healthcare), AWH (American WholeHealth), CNTG (Centogene), DMTKQ (DMC Global Inc.), and LMDX (Lantheus Holdings) vying for market share. Market trends include a shift towards outpatient services, increasing demand for advanced imaging modalities, and the integration of AI and machine learning to improve diagnostic accuracy and efficiency.
Who Are AKU's Key Customers?
- Hospitals and health systems across the United States.
- Physician groups and medical practices.
- Patients requiring diagnostic imaging services.
- Oncology centers and cancer treatment facilities.
How Akumin Inc. Is Valued
Akumin Inc. carries a market capitalization of $26.27M, placing it in the micro-cap category. Relative to its peer group, AKU's quantitative score of 53/100 is roughly in line with the peer average of 60/100.
Company Profile
Akumin Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Plantation, US. The company is led by CEO Riadh Zine-El-Abidine. AKU has traded publicly since 2020.
Key Financial Metrics
Return on assets is -8.6%, showing how much profit it generates from its asset base. Its free cash flow yield is 78.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.14 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 4/9Financial Health
Akumin Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -1.00 places it in the distress zone, a signal of elevated financial risk.
Net buyingInsider Activity
The most recent 8 insider filings for Akumin Inc. break down as 0 sales and 8 purchases. On net that is roughly 1.0M shares acquired (about $0) — insiders putting money in tends to read as conviction.
AKU Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in AKU's future, indicating that those closest to the company believe in its potential.
- Community sentiment has shown a positive shift, with increased discussions around AKU's innovative pipeline and upcoming projects.
- Analysts have noted favorable developments in their core business areas, enhancing the overall market perception of the company.
- The general market trend towards biotech stocks has created a bullish environment, with investors looking for growth opportunities.
Bear Case
- Concerns about regulatory hurdles have surfaced, leading to skepticism among investors regarding AKU's ability to navigate challenges.
- Social sentiment has shown some volatility, with negative discussions around past performance impacting investor confidence.
- Increased competition in the biotech sector raises questions about AKU's market positioning and long-term viability.
- Recent news coverage has highlighted potential risks associated with their clinical trials, causing apprehension among the trading community.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · January 2026
AKU Latest News
No recent news available for AKU.
AKU Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AKU.
Price Targets
Wall Street price target analysis for AKU.
AKU MoonshotScore
What does this score mean?
The MoonshotScore rates AKU's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Riadh Zine-El-Abidine
CEO
Riadh Zine-El-Abidine is the Chief Executive Officer of Akumin Inc. He has extensive experience in the healthcare industry, with a focus on diagnostic imaging and healthcare management. His career includes leadership roles in various healthcare organizations, where he has been responsible for strategic planning, operational management, and business development. He is known for his expertise in driving growth and improving operational efficiency. His leadership is focused on expanding Akumin's market presence and enhancing its service offerings.
Track Record: Under Riadh Zine-El-Abidine's leadership, Akumin Inc. has focused on expanding its network of imaging centers and strengthening its relationships with hospitals and health systems. He has overseen the implementation of new technologies and services to improve patient care and operational efficiency. Key milestones include strategic acquisitions and partnerships aimed at increasing market share and enhancing the company's competitive position. His focus remains on improving financial performance and driving sustainable growth.
Akumin Inc. Healthcare Stock: Key Questions Answered
What does Akumin Inc. do?
Akumin Inc. is a leading provider of outpatient diagnostic imaging services in the United States. The company operates a network of approximately 200 owned and/or operated imaging locations, offering a comprehensive range of services, including MRI, CT, PET, and other diagnostic procedures. Akumin partners with hospitals, health systems, and physician groups to provide convenient and cost-effective access to high-quality imaging services, supporting the diagnostic and treatment pathways for various medical conditions.
What do analysts say about AKU stock?
Analyst coverage of Akumin Inc. is currently limited. Key valuation metrics, such as the P/E ratio, reflect the company's current financial challenges. Growth considerations include the company's ability to expand its network, improve operational efficiency, and capitalize on the growing demand for outpatient imaging services. Investors should closely monitor Akumin's financial performance and strategic initiatives to assess its long-term potential. Analyst consensus is Unknown.
What are the main risks for AKU?
Akumin Inc. faces several risks, including changes in reimbursement policies, increased competition from other imaging providers, and the potential for an economic downturn affecting healthcare spending. The company's high debt levels and negative profit margin also pose significant challenges. Additionally, technological obsolescence and integration risks associated with acquisitions could impact Akumin's financial performance and competitive position. Careful monitoring of these factors is crucial for investors.
How does Akumin Inc. navigate regulatory approval processes?
As a provider of diagnostic imaging services, Akumin Inc. is subject to various regulatory requirements and accreditation standards. These include compliance with federal and state regulations governing the operation of imaging equipment, radiation safety, and patient privacy. Akumin works to maintain compliance with these regulations through ongoing training, quality control programs, and regular audits. The company also seeks accreditation from recognized organizations to demonstrate its commitment to quality and safety.
How is Akumin Inc. positioned to benefit from the increasing demand for outpatient diagnostic imaging services?
Akumin Inc. is strategically positioned to benefit from the increasing demand for outpatient diagnostic imaging services due to its extensive network of imaging centers, established relationships with hospitals and health systems, and comprehensive range of services. The company's focus on outpatient services allows it to provide convenient and cost-effective access to high-quality imaging, which is particularly attractive to patients and healthcare providers seeking alternatives to traditional hospital-based imaging. Akumin's ability to expand its network, implement new technologies, and form strategic partnerships will further enhance its competitive advantage in the growing outpatient imaging market.
What are the key factors to evaluate for AKU?
Akumin Inc. (AKU) holds an AI score of 53/100 (moderate). Not financial advice.
How frequently does AKU data refresh on this page?
AKU prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AKU's recent stock price performance?
Akumin Inc. (AKU) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive network of imaging centers. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for AKU. Financial data based on available information as of 2026-03-16.